Skip to main content
ROVI Subsidiaries
Spain
Germany
France
Italy
Poland
Portugal
United Kingdom
Language
Spanish
Spanish
English
English
English
Español
Home
ROVI
History
Group structure
Business units
International expansion
Strategy
Licenses
Contact
Products
Prescription Pharmaceuticals
Hospital Products
Manufacturing
CDMO
Own product Manufacturing
R&D
Shareholders and Investors
The share
Investor's Calendar
News
Financial and Business Information
CMNV Communications
ESG
Corporate Governance
Telematic assistance access
Prior Registration On-Line Attendance
On-Line Attendance
Sustainability
Responsible governance
Commitment to people
Environmental Commitment
Ethics Channel
Media
FAQS
News
ROVI up to date
Contact
Work with Us
TELEMATIC ASSISTANCE ACCESS
Home
News
ROVI Rating ESG 2020
Fri, 25/09/2020 - 14:25
0 min
Download related document
Select rating
Give ROVI Rating ESG 2020 1/5
Give ROVI Rating ESG 2020 2/5
Give ROVI Rating ESG 2020 3/5
Give ROVI Rating ESG 2020 4/5
Give ROVI Rating ESG 2020 5/5
No votes yet
Related
ROVI reports operating revenue growth of 8% and net profit growth of 83%
Today, Laboratorios Farmacéuticos Rovi, S.A. (BME: ROVI), a pan-European pharmaceutical company specialising and engaging in the...
9 min
27/07/2020
ROVI and Moderna Announce Collaboration for Outside the United States Fill-...
Moderna, Inc. (Nasdaq: MRNA), a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a...
3 min
09/07/2020
ROVI reports operating revenue growth of 23% and EBITDA growth of 68%
Operating revenue increased by 23% to 101.0 million euros in the first quarter of 2020, mainly driven by the strength of the specialty...
7 min
13/05/2020
See More
Email
Facebook
Twitter
LinkedIn